Showing 581-590 of 696 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-15/23311/2022 in Review
https://practicaldermatology.com/topics/other-dermatology/2022-in-review/23833/The past year brought many new approvals and advances to dermatology for improved patient care.The ABCDEs of AI for Skin Cancer Detection
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-abcdes-of-ai-for-skin-cancer-detection/23695/Key considerations for dermatologists as AI continues to expand.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-8/23162/Practical Considerations for Treating Psoriasis: Focus on Secukinumab
https://practicaldermatology.com/topics/psoriasis/practical-considerations-for-treating-psoriasis-focus-on-secukinumab/20841/A Review of Complications of Biologic Therapy for Psoriasis
https://practicaldermatology.com/topics/general-topics/1109_02-php/22053/Therapeutic success requires clinicians to understand emerging and established safety concerns.Diversity and Equity in Dermatology
https://practicaldermatology.com/topics/practice-management/diversity-and-equity-in-dermatology/23456/- Michael R. Stewart Named Next President and CEO of MELA Scienceshttps://practicaldermatology.com/news/20141119-micheal_r_stewart_named_next_president_and_ceo_of_mela_sciences/2459057/MELA Sciences, Inc. developer of the MelaFind(R) system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, announced that its Board of Directors has named Michael R. Stewart, 57, as the company's n
- Study: R&R Complex Superior to Ceramide Moisturizer for Dermatoporosishttps://practicaldermatology.com/news/study-rr-complex-superior-ceramide-moisturizer-dermatoporosis/2468413/Results from a split-arm study suggest that use of a new product (ReFORM & RePAIR COMPLEX with TriHex Technology® [R&R]) resulted in more skin improvements than a ceramide moisturizer in patients with dermatoporosis (DP). Conducted over 24 weeks, the trial included 38 participants
- James R. Headley Joins ELEVAI LABS as Strategic Advisorhttps://practicaldermatology.com/news/james-r-headley-joins-elevai-labs-as-strategic-advisor-a-strategic-advisor/2461450/Cosmetic industry veteran James R. Headley is joining